Please login to the form below

Not currently logged in
Email:
Password:

Therachon poaches Shire’s Aled Williams

He becomes the biotech’s chief commercial officer and head of patient access

Aled WilliamsTherachon, a clinical-stage biotechnology company, has appointed Aled Williams to the position of chief commercial officer and head of patient access.

Williams has more than 25 years’ experience in healthcare and pharmaceuticals and most recently he served as vice president and global strategy head for rare gastrointestinal diseases at Shire.

There he was responsible for the commercialisation and development of Gattex/Revestive (teduglutide) for short bowel syndrome.

Williams said: “I am excited to be joining the talented leadership team at Therachon and I look forward to working with the Therachon team and the whole medical and patient community in developing TA-46, and advancing Therachon’s pipeline of drug candidates that aim to bring a transformational new therapy to those in the achondroplasia community.”

Prior to his time at Shire, Williams held leadership positions at Bristol-Myers Squibb, Novartis and Roche.

Commenting on the recent appointment, Luca Santarelli, chief executive officer of Therachon, said: “Aled has spent many years leading companies through the development of successful rare disease programmes, including the expansion of patient outreach and commercial capabilities.

“We believe his considerable leadership experience in rare diseases will contribute to Therachon’s continued growth as we move into the clinic, establish our network of key partners among clinicians and patient organisations.”

23rd March 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...